1. DDIS-26. HIGH-THROUGHPUT DRUG SCREENING OF MENINGIOMAS IDENTIFIES HDAC INHIBITORS AS PROMISING TARGETS ACROSS GRADES. (11th November 2019) Authors: Tatman, Philip; Fringuello, Anthony; Wroblewski, Teddy; Scherer, Sam; Foreman, William; Ryan Ormond, D; Damek, Denise; Lillehei, Kevin; Jensen, Randy; Graner, Michael Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi68 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DDRE-45. HIGH-THROUGHPUT SCREENING OF EPIGENETIC COMPOUNDS FOR THE TREATMENT OF CHORDOMA IDENTIFIES POTENTIAL NOVEL THERAPEUTICS. (12th November 2021) Authors: Wroblewski, Tadeusz; Tatman, Philip; Fringuello, Anthony; Scherer, Sam; Foreman, William; Damek, Denise; Youssef, Samy; Lillehei, Kevin; Ormond, David; Graner, Michael Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi84 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DDRE-20. HIGH-THROUGHPUT SCREENING OF FDA-APPROVED COMPOUNDS IN GLIOMA AND GLIOBLASTOMA IDENTIFIES NOVEL THERAPEUTICS. (12th November 2021) Authors: Wroblewski, Tadeusz; Tatman, Philip; Fringuello, Anthony; Scherer, Sam; Foreman, William; Damek, Denise; Youssef, Samy; Lillehei, Kevin; Ormond, David; Graner, Michael Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi78 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. DDRE-10. SCREENING OF EPIGENETIC COMPOUNDS IN GLIOMA AND GLIOBLASTOMA IDENTIFIES NOVEL THERAPEUTICS FOR THEIR POTENTIAL TREATMENT. (12th November 2021) Authors: Tatman, Philip; Wroblewski, Tadeusz; Fringuello, Anthony; Scherer, Sam; Foreman, William; Damek, Denise; Youssef, Samy; Lillehei, Kevin; Ormond, David; Graner, Michael Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. DDRE-43. SCREENING OF FDA-APPROVED COMPOUNDS FOR THE TREATMENT OF CHORDOMA, WITH IN VIVO VALIDATION USING THREE DIFFERENT XENOGRAFT MODELS, IDENTIFIES BRIGATINIB AS A POTENTIAL TREATMENT. (12th November 2021) Authors: Tatman, Philip; Wroblewski, Tadeusz; Fringuello, Anthony; Scherer, Sam; Foreman, William; Damek, Denise; Youssef, Samy; Lillehei, Kevin; Ormond, David; Graner, Michael Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi83 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗